Harvard College

The General Hospital Corporation

Dana-farber-cancer Institute Inc.

The Broad Institute, Inc.

Curtis Huttenhower

Ramnik Xavier

Gwo-Shu Mary Lee

Hera Vlamakis

Christopher Sweeney

Svitlana Tyekucheva

Lorelei Mucci

Andrew Brantley Hall

Travis Gerke

Gwo-sho Mary Lee

Daniela Bornigen

Xiaodong Wang

Kristina Jordahl

Moran Yassour

The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.

Compositions and methods for screening and identifying clinically aggressive prostate cancer

This application provides for methods of treatment for IBD, especially in subjects who havespecies orgroup IBD strains as a component of their microbiome. The application also provides for methods of diagnosing IBD, as well as kits for use in the claimed methods.

Methods of treating and diagnosing IBD associated with r. gnavus and/or r. gnavus group IBD colonization

Growing community of inventors

Boston, MA, United States of America

Curtis Huttenhower